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4. Introduction. 
4.1. Historical remarks. 
 
 
Heart Failure (HF) is an increasing health problem with an incidence of 0.5 % and a 
prevalence of 1-3 % in the western world.  Ten percent of HF patients are in NYHA class IV 
with one year mortality up to 50 %1;2, depending on the response to modern HF treatment3;4.  
The treatment of choice for selected patients with the most dubious prognosis and the capacity 
to benefit, is heart transplantation (HTx)5;6.    
The first human HTx was performed in South Africa by Dr. Bernard in 1967. With a 
24 year old donor, the patient was improving hemodynamically, but succumbed 18 days after 
surgery due to pneumonia7. Steroids were deployed in clinical transplantation in the 1960s. 
Cyclosporine (CsA) was first used in renal transplantation in 1979 and introduced in HTx at 
Stanford University in California in 19808. The diagnosis of rejection was improved by the 
introduction of Caves-Schulz bioptome in 1975 and the Billingham rejection scoring system 
1974.  A more specific and balanced immunosuppression improved two years survival to 
nearly 80 %, an inspiration for the first Norwegian HTx in 19839.   
The first HTx patient in Norway is still alive and with excellent quality of life. Mean 
survival after HTx in Norway is 12.3 ± 5.3 years, superior to most international results 
reported by the International Society of Heart and Lung Transplantation (ISHLT)10-12.  
Norway was in 2008 reported with 7.7 HTx/mill/year, with a maximum of 45 in 2003. 
However, due to donor organ shortage, only 30 to 35 HTx are performed in Norway yearly 
(fig 1), making each donor organ a special resource utilized to the best of potential recipients, 
a selection process following international guidelines.  
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Figure 1. Number of Heart Transplantations performed yearly at Rikshospitalet.  With 
courtesy to dr. T. Leivestad, Institute of Immunology. Oslo University Hospital 
Rikshospitalet. 
 
 
 
 
4.2. Hemodynamics before and after HTx. 
 
HF involves important and crucial hemodynamic changes that require additional attention for 
optimal treatment as well as for risk stratification both pre- and post-HTx3;12;13.  Pulmonary 
hypertension (PH) due to left sided heart failure is common and carries a poor prognosis14;15. 
Severe irreversible PH is one of the few absolute contraindications to HTx5.  The rationale is 
that a normal donor heart is not capable of maintaining adequate right ventricular stroke 
volume against an elevated and fixed pulmonary vascular resistance (PVR)16;17. Just what 
constitutes unacceptably high levels of PVR, with or without the use of vasodilatation test, is 
still debated11;18.  Guidelines concerning acceptable preoperative right heart hemodynamics 
(RHH) to prevent right heart failure in the implanted heart were initially developed at 
Stanford University. International guidelines are published by the ISHLT working group and 
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have been slightly liberalized compared to the original Stanford protocol12.  The evidence for 
RHH guidelines is weak (class of evidence IIb) and is still based on small single centre 
reports. The value of repetitive right heart catheterization (RHC) while waiting for HTx is 
uncertain and the clinical and prognostic impact of elevated pulmonary pressures after HTx is 
scarcely described3;12.  
 
4.3. Immunosuppression in HTx recipients.  
 
New immunosuppressive strategies have improved survival after HTx and many centers have 
based their immunosuppressive strategy on triple-drug regimen consisting of calcineurin 
inhibitors (CNI; CsA and tacrolimus (TAC)), azathioprine (AZA)/mycophenolatemofetil 
(MMF) and corticosteroids11;19.  
CNI has contributed to lower rejection rates and favourable graft survival reaching 90 
% the first year after HTx11.  CsA is a prodrug and its immunosuppressive properties depend 
on the formation of a complex with cellular proteins called immunophilins consisting of the 
cyclophilin (which CsA binds to) and the FK binding system (which TAC binds to).  The 
CsA- cyclophilin complex inhibits calcineurin, which is responsible for activating the 
transcription of interleukin 2 (IL-2) and other cytokines. Inhibition of IL-2 reduces activation 
and function of T-cells and blocks the T-cell cycle in the G0 phase and limits activation of 
cytotoxic T-cells7;20. CsA has been approved for use as a primary immunosuppressant for 
more than 35 years and advances in formulation design and therapeutic drug monitoring have 
resulted in substantial improvement in clinical outcome20-22.  
TAC or FK-506 was discovered in 1984, launched in 1993, and has an increasing 
market among CNIs in HTx recipients, now reaching more than 50 %11;23.  The mechanism of 
action and effect as an immunosuppressant agent are much similar to that of CsA22;24.  
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Prolonged TAC with dosing once daily is now available, possibly improving recipient 
compliance, but still not recommended in HTx guidelines22;25. 
AZA, a purine analogue immunosuppressant was standard at our institution 1983-
2002, and replaced by MMF, a reversible inhibitor of inosine monophosphate dehydrogenase 
in purine biosynthesis which is necessary for growth and replication of T and B cells. 
Introduction of MMF reduced rejection and showed superior survival compared to AZA20;23. 
Corticosteroids are the third class of drugs to prevent rejection.  Many centres have 
tried to withdraw steroids due to side effects5. In our centre, 90 % of the recipients use 
steroids. 
Proliferation signal inhibitors (PSI), such as everolimus (EVE) and sirolimus, may 
represent an attractive renal sparing alternative to CNI therapy. They inhibit mammalian 
target of rapamycin (mTOR) causing blockage of T-cell activation and inhibits proliferation 
of smooth muscle cells by blocking cell replication in the G0 phase in addition to 
antiproliferative properties20;26. Multiple metabolites of the two agents make their 
immunologic properties uncertain19. Preliminary reports have demonstrated that these agents 
can replace CNI therapy in Tx recipients and allow an improvement in renal function without 
loss of immunosuppressant potency27-29. Others have reported high frequency of side effects 
of these agents30;31. Thus, there is still controversy about the degree of renal failure, to what 
time and whether as a substitute or in combination with CNI, that PSI should be introduced32. 
Compared to sirolimus, EVE has superior biochemical properties: higher biovailability, 
shorter half time, faster absorption and no loading dose required33. 
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4.4. Adverse effects of immunosuppression in HTx recipients. 
 
Although CNI inhibitors are first choice as main immunosuppressant in most centres, side 
effects include renal failure, hemodynamic perturbations and involvement in development of 
cancer and coronary allograft vasculopathy (CAV)11;34.  Nearly 30 % of HTx recipients 
develop renal dysfunction as early as one year post-HTx, an independent risk factor for both 
all-cause and cardiac mortality35-37.  
Acute renal failure (ARF) is a major contributor to morbidity and mortality in HF and 
cardiac surgery38;39. However, in the HTx setting the consequences of ARF are less well 
studied and most reports focus on long-term development of chronic renal failure (CRF)37. 
CNI induced nephrotoxicity occurs often within the first doses post-HTx due vasoconstriction 
of the preglomerular arterioles23. Chronic use of CNIs is characterized by glomerular 
sclerosis, interstitial fibrosis and thickening of capillary basement membranes seen in 25 % 
already six months post-HTx40. High prolonged CsA blood concentrations are known to 
predispose to chronic CNI induced nephrotoxicity19;20;41;42 . Chronic renal damage due to a 
diverse spectrum of diagnosis is usually not responsive to dose reduction and therapeutic 
action must therefore be taken before fibrosis has been established32;42;43.  
  . 
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5. Main aims of the study. 
 
 
1. To evaluate indices of pulmonary hypertension pre- and post-HTx and their prognostic 
significance on survival. 
 
 
 
2. To evaluate incidence and risk factors of ARF after HTx and the impact of ARF on 
prognosis. 
 
 
3. To evaluate early and late conversion from CNI based to everolimus based 
immunosuppression in HTx with focus on safety and renal improvement. 
 
 
4. To evaluate everolimus introduction and CNI reduction in maintenance TTx with emphasis 
on baseline GFR as marker of renal improvement. 
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6. Material and Methods. 
6.1. Study population. 
 
Oslo University Hospital Rikshospitalet is the only transplantation center in Norway and all 
HTx activity is located here. Patients were identified from our HTx database created in 1996. 
Data were retrospectively collected from 1983-96 and prospectively collected from 1996. All 
patients transplanted between 1983 and 2007 were included in studies on PH (n=500) and 
ARF (n=585).  In paper 1, 53 recipients were not included due to age below 16 years, 
recipients of multiple organs, re-HTx, mechanical tricuspid or pulmonary valve and missing 
data.  
         In paper 3, 31 HTx recipients with severe renal failure defined as eGFR ≤ 30 
ml/min/1.73m2 were included and divided in two groups according to time since HTx.  Group 
1 consisted of 16 patients transplanted within the last year [median 5.5 (1.3-8.5) months] 
before CsA elimination. One patient was not analyzed for primary end point due to less than 
24 months follow up. Fifteen long term recipients were recruited (Group 2). Due to early 
withdrawal and deaths, 10 patients 81 (39-109) months since HTx were analyzed for change 
in renal function defined as primary end point.  
          Paper 4 was a 12-month, open-label, multicenter, randomized, controlled study in 
Scandinavia (inclusion period December 2005 to March 2008) where 282 maintenance 
thoracic organ recipients (TTx) (190 HTx and 92 lung Tx) were randomized to continue their 
current immunosuppressive regimen or start everolimus therapy with a pre-defined reduction 
in CNI exposure. In this thesis discussion will mainly focus HTx recipients.   
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6.2. Right heart catheterization. 
 
RHC was performed using a Swan-Ganz pulmonary artery thermodilution catheter (Baxter 
Health Care Corp., Santa Anna, Ca., USA) or a Coumand catheter (for Fick method) before 
HTx, 2-3 weeks, 6 months and thereafter yearly for the first 3 years after HTx. RHC was 
repeated every third month while on waiting list for HTx.  
The following pressures were recorded in mmHg: Right atrial mean pressure (RAM), 
systolic pulmonary artery pressure (SAP), mean pulmonary artery pressure (MAP) and mean 
pulmonary capillary wedge pressure (PCW). Cardiac output (CO) was measured by the Fick 
technique or thermodilution, and cardiac index (CI) calculated by dividing CO by body 
surface area. The transpulmonary gradient (TPG) was obtained by subtracting PCW from 
MAP and PVR (in Wood units (WU)) by dividing TPG by CO.  For examination of CO, the 
Fick technique was used to measure CO the first 7 years, later replaced by the thermodilution 
technique44. 
For listing of patients for HTx, two of the following three criteria had to be fulfilled: 
SAP ≤ 50 mmHg, TPG ≤ 10 mmHg and PVR ≤ 2.5 WU. If not, sodium-nitroprusside, for 
reversibility testing, was given intravenously (iv.) (maximal dose 8µg/kg/min), until criteria 
were fulfilled or unacceptable side effects appeared. Systemic arterial blood pressure (SBP) 
was monitored.  In case of unacceptable RHH despite sodium nitroprusside testing, 
optimization of oral medication was performed, including diuretics iv. or introduction of 
IABP before a new vasodilation test was performed45.  
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6.3. Immunosuppressive protocols. 
 
6.3.1. CNI in combination with steroids and MMF/azathioprine. 
 
From 1983 until 2002; CsA and AZA were started orally 2-4 hours preoperatively; CsA at a 
dose of 4 or 6 mg/kg according to estimated glomerular filtration rate (eGFR) below or above 
50 ml/min/1.73m2, and AZA 4 mg/kg.  Next dose of both agents were administered orally 12 
hours postoperatively and continued to achieve blood concentrations as in table 1 below.  
2002-2009; Premedication was restricted to 1 g MMF. CsA was administered iv. as a 4 hour 
infusion immediately postoperatively and continued twice daily until oral medication was 
possible and then continued as in table 1.  
2009-2010; Induction therapy with basiliximab was introduced to patients with eGFR below 
50 ml/min/1.73m2. First dose was administered 4 hours preoperatively and second dose at day 
four post-HT. CsA was initiated orally first or second day depending on renal function.  
Patients with eGFR ≥ 50 ml/min/1.73m2 initiated CsA and MMF preoperatively as before 
2009.  
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Table 1. History of immunosuppressive protocols at Oslo University Hospital Rikshospitalet. 
Agent Time  CsA pre/per op C0 < 1 mo. C0 1-3 mo.  C0  4-12 mo C0 > 12 mo. 
CsA 1983-2002 4-6 mg/kg 
preop. 
250-350 µg/l 150-250 µg/l 120-200 µg/l 60-120 µg/l  
CsA 2002- iv. 1mg/kg 
postop. 
250-350 µg/l 150-250 µg/l 120-200 µg/l 60-120 µg/l  
AZA 1983-2002 4 mg/kg 50-150 mg/d 50-150 mg/d 50-150 mg/d 50-150 mg/d 
TAC 2000- NA 8-10 µg/l 6-8 µg/l 6-8 µg/l 4-6 µg/l 
MMF 2002- 1 g 1-3 g/d 1-3 g/d 1-3 g/d 1-3 g/d 
EVE+CsA* 2007- NA 4-6 µg/l + 125-175 µg/l 4-6 µg/l + 50-
125 µg/l 
6-8 µg/l + 100-25 
µg/l  
3-5µg/l+25-40 
µg/l 
EVE* 2005- NA NA 8-10 µg/l 6-10 µg/l   5-7 µg/l 
NA: not applicable.  CsA:cyclosporine A. AZA: azathioprine. TAC: tacrolimus. MMF: mycophenolatemofetil. 
EVE: everolimus.  *In combination with MMF/AZA and steroids. 
 
 
During all periods methylprednisolone was administered intravenously 
perioperatively, continued postoperatively as oral prednisolone at a dose of 0.2 mg/kg, and 
gradually reduced to a maintenance dose of 0.1mg/kg.  
 
6.3.2. Everolimus without concomitant CsA. 
 
Within the first year after HTx, EVE without CsA was introduced with a dosage of 2.25 mg 
twice daily, while in long term survivors EVE was initiated 2.0 mg twice daily. Blood 
concentration levels were targeted as in table 1. MMF was reduced in case of side effects due 
to increased exposure after CNI withdrawal. Steroids were continued as before switch. In case 
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of major surgery, EVE was replaced by CsA one week before and reinstituted two weeks after 
the operation or until proper wound healing was accomplished46.   
 
6.3.3. Low dose Everolimus and low dose CsA. 
 
 
In the NOCTET trial, EVE was initiated overnight with a starting dose of 0.75 mg b.i.d. and 
with a target concentration in the range 3-8 µg/l. After an initial period with a significant 
increase in infections in the EVE arm, a reduction in concentration to 3-6 µg/l was 
recommended by the data safety committee. Upon initiation of EVE a parallel reduction of 
CNI dosage was performed to achieve a trough level reduction of 30-70 % compared to 
baseline, with the target of achieving a CsA trough level <75 µg/l or a TAC trough level <4 
µg/l. For patients in the EVE group receiving CsA and MMF, a 25-50 % reduction in MMF 
dose was recommended one week after introduction of EVE with further MMF dose reduction 
as required. For EVE-treated patients receiving TAC, MMF treatment was to continue 
unchanged unless medically necessitated. MMF level measurements were performed based on 
the individual clinician’s discretion. Concomitant medication with AZA, with or without 
steroid therapy, was continued according to local practice. 
 
6.4. Definition of end points. 
 
6.4.1. Mortality. 
 
Mortality data for all patients were collected from the Norwegian population register and 
cause of death obtained from recipients local hospital.  
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6.4.2. Hemodynamic end points. 
 
The hemodynamic protocol is described under 3.2. Our end points are based on review of the 
literature identifying 47 studies describing 72 populations of healthy volunteers that were 
examined for pulmonary arterial pressure.  Normal resting MAP was 14.0 ± 3.3 mmHg, with 
the upper limit of 20.6 mmHg.  A resting MAP of 18-20 mmHg was defined as a “grey 
zone”47. Normal value for PVR is reported 0.25- 1.5 WU44.  In the context of HTx, 2.5 WU is 
adequate in defining what is accepted for HTx and elevated PVR in our center.  ISHLT 
guidelines indicate 3.0 WU as acceptable level of PVR before reversibility testing is 
considered12.  
6.4.3. Renal end points. 
 
 
Serum creatinine measurement is easily available and widely used at low cost. Estimated GFR 
was based on the MDRD formula [GFR (mL/min/1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 
x (0.742 if female) x (1.212 if African American) (conventional units)]. Based on the 
definitions from the Acute Kidney Injury Network (AKIN)48, patients were divided into two 
groups: No-ARF (Group 1) and ARF (Group 2, 3 and 4), based on serum creatinine changes 
from preoperatively to 7th postoperative day. ARF patients were divided into those increasing 
their creatinine < 26.4 mmol/l or < 50 % (Group 2), increasing their creatinine ≥ 26.4 μmol/l 
or ≥ 50 % (Group 3) or in need of early dialysis (group 4).  AKIN criteria represent changes 
in renal function within 48 hours. Serum creatinine values reported in our ARF article are 
based on 7th day measurements and therefore does not completely reflect the AKIN definition 
of change in renal function in 2 days. 
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The proposed Acute Kidney Injury Network (AKIN) criteria for the definition and 
classification of ARF.  
Stage 1: Increase in serum creatinine ≥ 26.2 μmol/L or increase to ≥ 150–199 % (1.50- to 
1.99-fold) from baseline.  Urine output < 0.5 mL/kg/h for ≥ 6 h.  
Stage 2: Increase in serum creatinine to 200–299 % (> 2.0–2.99 fold) from baseline.  Urine 
output < 0.5 mL/kg/h for ≥ 12 h. 
Stage 3: Increase in serum creatinine to ≥ 300% (≥3-fold) from baseline or serum creatinine ≥ 
354 μmol/L with an acute rise of at least 44 μmol/L or initiation of RRT  
Urine output < 0.3 mL/kg/h ≥ 24 h or anuria ≥ 12 h. 
 
In the NOCTET substudy, GFR was measured at baseline and at month 12 using Cr-
ethylenediamine tetraacetic acid clearance or an equivalent recommended method. Patients 
were categorized into 3 groups (mGFR 60-89, 30-59 and 20-29 ml/min/1.73m2, respectively) 
according to baseline mGFR by utilizing the National Kidney Foundation Disease Outcomes 
Quality Initiative (NKF-K/DOQI) Guidelines49. Data regarding urine dipstick chemical 
analysis at baseline and one year follow-up was available for a subset of patients. 
Dialysis through continuous arterio-venous hemo-diafiltration or intermittent dialysis 
sessions were carried out when transplant recipients showed signs of volume overload, 
[(RAM) > 12 mmHg)], peripheral oedema or pulmonary congestion in combination with 
urinary output < 0.5 ml/kg/hour over 24-48 hours with rapid creatinine increase by 50 
µmol/l/day over 2 days, serum creatinine rapidly rising above 200 µmol/l, or generally 
accepted criteria for dialysis. 
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6.5. Statistical analysis. 
 
 
Statistical analyses were performed with SPSS statistical software version 13.0 (SPSS inc. 
Chicago, IL). Results are presented as mean values ± standard deviation or median with 
interquartile range. Student’s t-test was used for normally distributed continuous variables and 
Mann-Whitney test for other continuous variables. Categorical variables were compared using 
the chi-square test. Group comparison over time was made using one-way Anova. A two-
sided p < 0.05 was considered statistically significant.  Kaplan-Meier analysis with log-rank 
test was performed to compare the number of events in the two groups. Cox proportional 
hazard analysis, including all variables significant upon univariate analysis (p <0.05), was 
performed to determine the independent variables for all-cause mortality and graft loss. All 
retransplants (n=11) were in this context considered as deaths. Propensity score, to identify 
variables at different time periods was used including three different methods (binary logistic, 
stratification, matching). 
 
6.6. Ethical consideration. 
 
As our HTx database is approved by the The Institutional Review Board at our hospital as 
well regional ethical committee, no ethical dilemmas were considered in paper 1 and 2. The 
NOCTET trial [Clinicaltrials.gov (unique registration number NTC00377962)] was approved 
by the national ethics committee in respective countries and the study was carried out in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, 
applicable local regulations and the Declaration of Helsinki. 
For the recipients in paper 3, development of a local protocol was performed to offer 
an alternative immunosuppression to those recipients with severe renal failure caused by CNI 
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exposure.  For the long term users the development of renal failure over the last years and a 
possibility of ending in dialysis within 1-2 years were considered as a proper reason to 
discontinue CNI medication22.   
All patients were informed about renal failure as a predictor in HTx.  Information 
about the possibility of CNI avoidance was given in a consultation between a dedicated study 
physician and each potential participant.  Patients were informed about possible side effects 
and were free to accept the conversion from CNI to EVE.  They were also free to withdraw at 
any time point and return to CNI treatment.  
 
7. Summary of papers. 
 
Paper 1. Pulmonary hypertension in heart transplantation: discrepant prognostic 
impact of preoperative compared to one year postoperative right heart hemodynamics. 
We wanted to evaluate the natural course and impact of pre- and post-operative right heart 
hemodynamics (RHH) in 500 consecutive HTx recipients. The main findings in the study 
were: (i) RHH before HTx are not predictive for survival after HTx as long as patients with 
severe PH are reversed by vasodilator administration, (ii) repeated RHC, while waiting for 
HTx seems to be of limited value, (iii) hemodynamic variables improve to near normal values 
within the first 2 postoperative weeks in most HTx recipients, while (iv) RHH indicating PH 
one year after HTx are strong independent risk factors for long term survival.   
 
Paper 2. Acute renal failure early after heart transplantation: risk factors and clinical 
consequences. 
We wanted to examine the incidence, risk factors and implication of acute renal failure (ARF) 
after HTx. Our main findings were that ARF occurred in 12 % after HTx. ARF was associated 
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with increased short-term mortality and correlated to the degree of ARF based on AKIN 
criteria. ARF was not a risk factor for later need of dialysis or kidney transplantation.   
The strongest determinant of developing ARF was CsA given intravenously. 
 
Paper 3. Benefit of early conversion from CNI-based to everolimus based 
immunosuppression in heart transplantation. 
We wanted to evaluate the effect of CNI elimination and EVE introduction in HTx recipients 
with severe renal failure early and late after HTx to evaluate the potential in renal 
improvement. Our results suggest that conversion from CNIs to EVE is safe and demonstrate 
substantial improvement in renal function among those converted within the first year after 
HTx.  In long term survivors with longer exposure to CNIs there was no improvement, but 
possibly stabilization, in renal function.  
 
Paper 4. Improvement in renal function after everolimus introduction and calcineurin 
inhibitor reduction in maintenance thoracic transplant recipients: the significance of 
baseline GFR. 
In this sub-study of the NOCTET trial we wanted to evaluate the potential improvement in 
renal function among recipients with different stages of renal failure.  Our findings were that 
introduction of low dose EVE and parallel CNI reduction significantly improved renal 
function amongst maintenance TTx patients with pre-existing moderate and advanced, but not 
mild renal failure. However, pharmacological intervention with EVE needs to be considered 
at a relatively early stage after transplantation as potential improvement seems to be more 
effective during the first years after TTx.  
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8. Discussion. 
 
Despite a rather intense research and focus on mechanical circulatory support, the field of 
HTx has continued to evolve. Progress has been made over the last years to minimize 
complications caused by immunosuppression, otherwise reducing both quality of life and 
increasing morbidity and mortality.  Successful HTx relies on a thorough candidate selection, 
donor availability and preservation, perfect surgery, close follow up and patient compliance. 
Our program is based on traditionally accepted guidelines, but there are few randomized trials 
to support the scientific evidence in HTx.  
 
8.1. Pulmonary hypertension in heart transplantation. 
 
8.1.1. Pulmonary hypertension before heart transplantation. 
 
 
 
PH is reported in up to 80 % of HF patients, depending on the definitions14. The number of 
patients with preoperative MAP > 20 mmHg among our HTx recipients is 84%, confirming 
that the sickest candidates selected for HTx also have the highest pulmonary pressures18. The 
presence of PH is associated with worse outcomes in non-transplanted HF patients, regardless 
of ejection fraction and stage of HF13-15, and development of RV failure post-HTx prognosis 
is further aggravated by irreversible PH50;51. Presence of PH is probably an evidence of more 
disease burden and often complicated multi-morbidity.  
Our patients with the most severe PH were males, diabetics and with a background of 
ischemic heart disease, risk factors that vary in previous reports3;5;14;18. They also had 
increased systemic blood pressure, an additional afterload burden causing more intense 
backward failure and increased pulmonary pressures52;53. Age was not a predictor for PH 
neither before nor after HTx, even though pulmonary pressures increase with age both at rest 
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and during exercise in healthy controls14;54. In contrast to a small previous report, smoking 
was not a predictor for PH suggestive that heart failure hemodynamics as the driving force 
and more prominent than changes caused by age and smoking55. 
Our reversibility protocol for PH is relatively aggressive and a very limited number of 
patients with severe PH are non-responders to vasodilation testing compared to other reports. 
Importantly, responders to vasodilatation faced similar prognosis as recipients with acceptable 
pressures. Our results therefore challenge the opinion of a poor prognosis for those with the 
highest pressures responding to vasodilation.  No absolute PVR cut off is reported in regards 
to post-HTx survival, but rather replaced by the recognition of elevated pulmonary pressures 
and PVR as incremental risk factors with increasing values11;17. However, patients with 
irreversible PH can in the present era be candidates for LVAD treatment, allowing otherwise 
suitable HTx candidates to be placed on the waiting list56-58. With third generation continuous, 
non-pulsatile LVAD they face the same prognosis post HTx as patients with acceptable 
RHH11;59. 
 HF changes in the pulmonary circulation usually precede changes in systemic 
hemodynamics. Patients with chronic LV dysfunction may develop PH due to a backward 
failure that is largely reversible with normalization of LV filling pressures.  However a 
sustained and excessive exposure to pulmonary venous hypertension leads to functional and 
structural changes in the pulmonary vasculature, initially in the capillaries and later in the 
arterioles and arteries60.  The exact relation between PH and structural changes in the 
pulmonary circulation is not fully understood and is probably individual due to response and 
sensitivity to changes in endothelial nitric oxide production, decreased expression of 
angiotensin converting enzyme, increased levels of endothelin and proinflammatory 
cytokines52. While permissive genotypes could possibly explain these variations, studies in 
this field have yet to be performed61 (fig 2). 
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Figure 2. Model for development and consequence of pulmonary hypertension. Reproduced 
with permission from Park and Mehra. J Am Coll Cardiol. 2012 
 
A close relationship between pulmonary pressures and PCW at baseline and a parallel 
reduction during vasodilation test suggests that left heart filling pressures is the main 
component of PH in HF and a simple response to chronically elevated left-sided filling 
pressures coupled with dynamic interaction between the two ventricles12;53. On the other hand, 
PCW decreased more than MAP and of the 135 patients in need of vasodilation, 35 % 
increased their TPG, and 16 % increased TPG to more than 20 mmHg as an indication of 
structural changes in the precapillary vasculature bed after longstanding HF in a subgroup of 
patients15.  
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8.1.2. Repeated catheterizations while waiting for heart transplantation. 
 
 
Our waiting list for HTx is relatively short compared to other countries. In our cohort, RHH 
were stable while waiting for HTx. One hundred patients were recatheterized in the waiting 
period. Most of the patients improved their RHH but 10 out of 70 patients went from 
acceptable pressures to need of vasodilation test. Most important, no patients developed fixed 
PH, and none had to be taken off the list.  The data on RHH while waiting for HTx is scarse 
and guidelines for patients in need of reversibility test are based on level of evidence 1C12.  
Our strategy with quarterly visits in addition to a close cooperation with local “heart failure 
clinics” may reduce the number of patients deteriorating and who become ineligible for HTx. 
We also have a relatively low mortality rate (< 5%) on the waiting list supporting our 
arguments.  
 
8.1.3. Pulmonary hypertension after heart transplantation. 
 
After HTx, when left sided filling pressures were lowered, the pulmonary venous congestion 
decreased with secondary reduction in pulmonary pressures62.  Pulmonary pressures showed a 
decline to near normal values within few weeks post HTx. Compared to those with acceptable 
pressures (Group 1), Group 2, in need of vasodilation, had a more impressive improvement 
than Group 1, but some recipients did not normalize pulmonary hemodynamics despite 
normalization of PCW pressures. Reduction in postoperative PH is previously reported with 
variable time to normalization18;63. 
 Increased MAP, as well as other hemodynamic parameters evaluated post-HTx were 
strong predictors of late mortality. PCW and RAM were the only hemodynamic parameters 
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similar between two groups with post-HTx MAP above or below 20 mmHg. We suggest that 
these patients` additional risk may be caused by structural changes in the pulmonary 
vasculature, not reversed by LV unloading64. MAP, CI and TPG were robust predictors for 
mortality also after 6 months, 2 and 3 years (data not shown) as well as PVR 2 weeks post-
HTx, shown in another study from our hospital (in press) (ISHLT 2012 abstract 166)65. 
Despite lack of data, medication proven efficacious in precapillary PAH patients, such as 
phosphodiesterase inhibitors and endothelin receptor antagonists, are being used to manage 
other forms of PH63 (ISHLT 2012 abstract 131). Although this approach may be justified in 
carefully selected patients with TPG out of proportions and reactive PH, medication may be 
ineffective or even harmful for most of HTx recipients with PH66;67. So far no therapeutic 
option has been validated to improve the prognosis of those with elevated MAP after HTx, 
reflecting the lack of focus on these recipients at risk15;22.   
 PH is fairly common shortly after HTx68;69. Risk factors for developing MAP > 20 
mmHg at one year were unfavorable preoperative hemodynamics in addition to male donor 
organ. Correlation between preoperative and at one year post-HTx MAP was poor (r = 0.236), 
reflecting the multitude of factors influencing postoperative RHH. Male donor organ as risk 
factor was stronger for women than for men and there were a higher proportion of male 
organs in the group with elevated MAP at one year post-HTx.  
 
8.2. Renal function before and after HTx. 
 
Heart failure with reduced CO often aggravates renal disease or initiates renal impairment due 
to hypoperfusion3.  Activation of the RAS system leads to salt and water retention that also 
paradoxically worsen the cardiac function and leads to venous congestion and a reduction in 
tissue perfusion70. Renal function is a strong independent predictor of long-term adverse 
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outcome in HF patients, as well as in HTx recipients35;38;71;72. New research and treatment 
modalities target renal protection both early and late after HTx34. 
 
8.2.1. Assessment of renal failure. 
 
 
ARF is defined in 3.4.3.  The true definition of acute kidney injury (AKI) is an abrupt 
reduction in kidney function during 48 hours48. Dialysis was usually initiated before a 2-3 
times increase in baseline creatinine was achieved, usually due to reduced diuresis and 
volume overload. An ideal definition of ARF in our HTx recipients would also be the change 
in renal function within 48 hours (AKIN criteria), of which we do not have the details to 
assess. Studies report a multitude of factors influencing renal function early 
postoperatively73;74.  Most reports define ARF as need for dialysis. Traditional risk factors for 
dialysis are reduced pre-HTx GFR, need of preoperative prolonged inotropes or mechanical 
circulatory support, complicated, prolonged or redo surgery and older recipients75;76. 
Independent of time period, the incidence of ARF was steady at 18 % before 
introduction of iv. CsA, when the need of dialysis increased up to an incidence of 23 % after 
2002. Dialysis is a more definite end point, but depends on the physician’s judgement and 
ability to interact when renal function declines.  Considerable variations in mortality for HTx 
ARF patients in dialysis probably reflect different criteria for initiation of dialysis. A Finnish 
study reports an incidence of dialysis of 25 % despite induction therapy, but incidences upto 
32% are reported for HTx patients with impaired pre-HTx renal function. Otherwise the need 
for dialysis varies between 6 % and 13 %73;75-77.  
 In paper 3 and 4, renal failure was classified according to the National Kidney 
Foundation Disease Outcome Quality Initiative. GFR < 30 ml/min/1.73m2 is classified as 
severe renal failure, while GFR between 30 and 59 ml/min/1.73m2 is defined as moderate 
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reduction. Most large randomized trials assess renal function with mGFR at baseline and 
follow up. In clinical work eGFR and creatinine are surrogate markers of renal function, 
reported equally as markers of prognosis36;38. In paper 4, mGFR and eGFR correlated with a 
r= 0.513, p< 0.001, and statistical analysis with eGFR would not significantly have altered the 
results in this sub-study, nor in the main study.  
 In paper 4, as in the landmark CONVERT trial, an mGFR improvement of 5 
ml/min/1.73m2 was chosen as a cut-off value of significant improvement in renal function 
after introduction of EVE in renal TX78.  
 
 
Table 2. Stages of chronic kidney disease. 
Stage Description GFR (ml/min/1.73m2) 
1 Kidney damage with normal 
or elevated GFR 
≥ 90 
2 Kidney damage with mild 
reduction of GFR 
60-89 
3 Moderately reduced GFR 30-59 
4 Severely reduced GFR 15-29 
5 Kidney failure  <15 or dialysis 
Chronic kidney disease is defined as either kidney damage or GFR < 60 ml/min/1.73m2 >3 
months including markers of damage in blood, urine test or imaging studies. 
 
Proteinuria is an early sign of renal disease and often represents a more general 
vascular damage. Proteinuria is associated with impaired renal prognosis and increased 
cardiovascular mortality even with a normal creatinine levels at time of measurements79.  It 
has been demonstrated that PSI agents can increase glomerular pressure and contribute to 
proteinuria and progression of pre-existing kidney damage80;81. PSI agents may also cause 
glomerolupathy or tubulointerstital disease related to interference with protein endocytosis in 
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tubular epithelial cells19;82.  Absence of proteinuria is reported as a discriminator for success 
when introducing EVE to reduce CNI and improve renal function83;84.  
             No internationally accepted protocol on proteinuria has been published for HTx 
recipients in contrast to renal Tx8.  In our institution initiation of EVE can be performed if 
protein/creatinine ratio < 50 mmol/ml. Patients with ratio between 50-100 mmol/ml are 
candidates for pre-treatment with ACE inhibitors or ARBs85;86. Recipients with ratio > 100 
mmol/ml are usually not candidates for EVE therapy, while a low dose EVE in combination 
with low dose CsA might be an alternative80. In our ARF study we did not quantify 
proteinuria.  In paper 3, proteinuria was only a clinical dilemma in a few patients in Group 2. 
In paper 4, proteinuria was not a clinical problem in a treatment strategy with low dose EVE. 
In low dose EVE or when introduced early post-HTx, proteinuria does not seem to be a 
problem, but need attention in long term recipients or in recipients with underlying renal 
disease8;83;87. Whether proteinuria induced by PSI is a negative predictor with consequences 
similar to proteinuria in native renal disease is unknown. CNI as a vasoconstrictor may 
unmask existing proteinuria in renal damage instead of proteinuria being induced by 
introduction of PSI. Manifest proteinuria has been a discriminant factor for successful 
introduction of EVE in renal, lung and heart Tx, and probably reflects renal disease beyond 
CNI induced vasoconstriction33. Factors reported to be associated with increased proteinuria 
after solid organ TX are poor renal function, loading dose with sirolimus, diabetes and 
histological abnormalities33. 
8.2.2. Determinants of acute renal failure. 
 
The most important factor for development of ARF was administration of iv. CsA early 
postoperatively. No HTx study has previously assessed renal function based on CsA 
administration and blood concentrations early postoperatively. Guidelines on iv. 
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administration of CsA concerning indication, once or twice daily, duration of infusion or 
concentration levels do not exist in the early postoperative setting22.  Vallentine et al 
demonstrated a better rejection profile after two six hour infusions compared to continuous 24 
hour infusion without considering the deleterious effect on renal function21. As high CsA peak 
concentration provides better protection from rejection, the side effects are greater 
vasoconstriction and reduced renal blood flow.  Regrettably, to further demonstrate the 
unfortunate circumstances of iv. CsA administration, we did not measure Cmax. 
CsA alters the balance between vasodilator and vasoconstrictor prostaglandins and 
increases renal arteriolar resistance and mesangial cell contraction88.  The intrarenal RAS 
system may also contribute to both nephrotoxic and hypertensive effects of CsA8. Prolonged 
CsA therapy causes chronic renal failure with a variety in severity. Older age, sex, underlying 
renal disease, different genotypes influencing CYP3A activity in renal cells and years with 
elevated CsA AUC predispose to chronic CsA nephrotoxicity21;89;90. Long term decreased 
renal blood flow induces glomerular sclerosis, with interstitial fibrosis and thickening of 
capillary basement membrane40. Once chronic renal failure is established decreasing CsA 
concentration or drug withdrawal will not necessarily improve renal function91.  
Recipients who developed ARF were older and received older donor hearts, a 
traditional risk factor of increased mortality10. Aging donor hearts implicate vulnerable 
initiation after cardioplegia and need of more inotropic agents to maintain adequate 
hemodynamics.  
Preoperative elevated RAM (CVP) was a predictor for dialysis and increased CO was 
an independent predictor for ARF. Patient in need of dialysis had lower CO and increased 
pulmonary pressures representing unfavourable RHH and reduced renal perfusion72. In HF 
patients, volume overload/ high RAM increase ventricular filling pressures and myocyte 
stretch44. Increase in force generation enables the healthy heart to eject the additional venous 
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return thereby increasing the stroke volume. For the patients in need of postoperative dialysis, 
hemodynamic parameters probably reflect the lack of contractile reserves and force velocity 
to maintain adequate circulation and renal perfusion. As both hemodynamic parameters and 
reduced pre-HTx GFR are predictors of ARF and dialysis post-HTx, it is once again a 
reminder that the cardiorenal syndrome is proven essential in HF and continuous importance 
in the HTx recipient92;93 (fig 3).  
In paper 3, all patients in Group 1 had postoperative ARF partly due to administration 
of CsA, as renal function improved markedly when our short term recipients had their CsA 
withdrawn and replaced by EVE. Paper 3 did not emphasize on predictors for the rapid post-
HTx increase in creatinine that all patients experienced. Additional mechanisms for CsA 
nephrotoxicity is likely in the per- and post-HTx setting, but CsA withdrawal significantly 
improved renal function that has remained stable with an extended follow up of 4.5 years. 
There was no control group to evaluate the natural course of renal failure for patients on 
traditional CsA medication, but a progression in renal impairment is described and 
experienced by all HTx physicians35. In a histopathological study of renal failure, a diverse 
spectrum of diagnosis indicate that long term recipients are at risk of nephrosclerosis and 
diabetic nephropathy as well as CNI toxicity243;94. These findings suggest a possible benefit in 
the form of stabilization of kidney function after a switch to EVE also among the long term 
users in Group 2. 
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Figure 3. Mechanisms of CNI nephrotoxicity. 
 
 
8.3. Immunosuppression in HTx. 
 
Our immunosuppressive protocol has traditionally been CsA based with conversion to TAC in 
case of CsA side effects such as gingivitis, hirsutism or repeated rejections24. After 
introduction of TAC in 1993, inferior results were initially reported compared to the new 
microemulsion CsA Neoral. Later studies have reported similar survival rates, even though a 
review from 2010 with meta-analysis were in favor of TAC20;24;95;96.  ISHLT report increasing 
use of  TAC, but more long term users switch from TAC to CsA based immunosuppression 
than vice versa5. Prolonged release formulation and mono-therapy with TAC has been proven 
safe, but without long term follow up97;98. 
In the later years EVE has been increasingly suggested used due to less nephrotoxicity. 
Reports on EVE in de novo HTx demonstrate variable results and randomized trials are 
ongoing. I will discuss the administration form of CsA in addition to the introduction of EVE 
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with focus on minimilization or elimination, blood concentration levels and timing for therapy 
intervention.  
8.3.1. Early postoperative peroral or intravenous CsA. 
 
Our traditional protocol introduced po CsA preoperatively to maintain adequate CsA levels 
early post-HTx.  CsA is liphophilic and absorbed in the upper gastrointestinal tract, with 
variable absorbtion the first days post-HT. The newer microemulsion form of CsA (Neoral) 
has more favorable outcome than the old oil formulation and greater bioavailability 
[(AUCoral/AUCiv)x(Doseiv/Doseoral)] that is approximately 30 % of iv. 
administration.20;21;89;99.  Iv. CsA resulted in a higher proportion of ARF. Unfortunately we do 
not have sufficient details to correlate iv. and po. CsA concentrations with the rejection 
profiles of the two subgroups of ARF. In the literature, iv. administration of CsA is also called 
induction therapy23. As newer induction agents have been developed, our experience with iv. 
CsA should indicate that this administration form should be limited to a minimum early 
postoperatively. ISHLT reports shows that induction therapy does not provide additional 
rejection efficacy compared to a non-induction strategy, results that contrast smaller reported 
studies5;20;100. As renal sparing strategy, induction therapy is proven effective and its use is 
widespread22;101. Guidelines recommend relatively high doses of CNI early post-HTx, 
especially from US centers. Different C0 recommendations complicate collaborate studies in 
European and US centers22;102 (ISHLT 2012 abstract 201).  
 
8.3.2. CNI reduction and everolimus introduction. 
 
 
  
Two major studies, including 1250 recipients, have been performed combining EVE and CNI 
in de novo HTx recipients. Both studies have replaced MMF or AZA with EVE and the blood 
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concentrations of CNI have remained rather high and renal protection has not been 
observed103 (ISHLT 2012 abstract 201). In other de novo studies, combination of CsA and 
EVE have not provided any renal improvement compared to CsA standard therapy in addition 
to MMF and steroids104;105. No renal protection was reported in an open de novo triple arm 
study with combination of TAC and sirolimus, compared to TAC or CsA in combination with 
MMF and steroids95. As a consequence of non-successful trials, a strategy for early 
introduction of EVE and CNI reduction has not been established and a substitution of PSI for 
MMF in addition to standard CNI concentrations are not recommended due to risk of 
enhanced CNI nephrotoxicity22.  
Studies including long-term HTx recipients are smaller and have not established a 
consensus on combination therapy of CNI and EVE. In non-randomized reports, CNI 
reduction or withdrawal with EVE replacement partly preserved renal function27;83;106.  
As CsA and EVE share the same glycoprotein in kidney tissue, concomitant therapy 
possibly potentiates renal toxicity. Co-administration of CsA microemulsion increased AUC 
for EVE concentrations by 168 %, but not vice versa, and a substantial CNI reduction has to 
be achieved before renal protection is observed89. Reports are often complicated with high 
frequency of adverse events and withdrawals due to overimmunosuppression32;105. 
The NOCTET trial included 282 TTx recipients more than 1 year after transplantation. 
Of 190 HTx recipients, our center included 78 patients. Paper 4 reports results from both HTx 
and lung Tx. Results were mostly comparable for the two groups, although slightly in favor of 
HTx in terms of beneficial effect on renal function.  The following discussion will focus on 
HTx. 
The NOCTET trial demonstrated that EVE introduction and parallel CNI reduction 
significantly improves renal function in maintenance TTx patients with an overall difference 
of 5.1 ml/min/1.73m2. However, there was a significant interaction with pretreatment renal 
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function, evidenced by a mGFR improvement of nearly 7 ml/min/1.73m2 and 5 
ml/min/1.73m2 in patients with baseline severely or moderately reduced mGFR, respectively. 
In contrast, no improvement was observed in patients with mGFR > 60 ml/min/1.73m2. 
Previous guidelines do not recommend a switch to EVE therapy amongst patients with severe 
pre-existing renal damage, an opinion challenged by our results and in a recent German 
review23;101;107.  
 Paper 4 demonstrated that this strategy is clinically relevant as 66% of patients with 
the most advanced CRF had an improvement of >5 ml/min/1.73m2 with EVE therapy as 
compared to 54% of patients with less severe pre-existing renal damage. It should be noted 
that the group with the most deranged renal function had higher CsA baseline concentrations 
than the two other groups. A further potential for renal improvement would probably be 
possible with CsA adjusted to a lower range as a correlation between CsA reduction and renal 
function is reported106.  The correlation between CNI reduction and mGFR improvement was 
only modest suggesting also other mechanisms contributing to improvement in renal 
function108. As improvement was limited to patients transplanted less than five years, 
intervention should be initiated before renal fibrosis is established.  
          After an initial period with a significant increase of infections in the EVE arm, a 
reduction in EVE blood concentration from 3-8 to 3-6 ng/mL was recommended by the 
control committee due to overimmunosuppression also experienced in other studies83 (ISHLT 
2012 abstract 201). Studies intending to improve renal function, de novo or in long term 
recipients, with concomitant EVE introduction report CsA concentrations that are too high to 
significantly improve GFR83;105. Poor adherence to planned CsA targets, the concern of CsA 
underexposure, distrust to EVE as rejection prophylaxis and risk of rejection in the early post-
HTx setting result in both EVE and CsA concentrations with secondary renal toxicity105 
(ISHLT 2012 abstract 201). 
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After increasing experience with combination therapy, CsA is in long term recipients 
in our center now aimed at 25-40 µg/l in combination with EVE 3-5 µg/l in addition to MMF 
and steroids. As interaction and low doses of both drugs often make target concentration hard 
to achieve, different dose (±25 mg) of CsA every second day is possible or CsA blood 
concentration in non-detectable range (< 25 ng/ml), with a C2 concentration > 180 ng/ml and 
EVE 4-6 ng/ml is a second alternative in order to reduce CsA substantially.  Our experience 
with EVE in combination with TAC is limited22.  
 
8.3.3. CsA elimination and everolimus introduction. 
 
Few reports exist on PSI without concomitant CsA after HTx, and most reports are on long 
term survivors27;28;31;109;110. Improvement in renal function is reported, but high frequency of 
adverse events and withdrawals complicates conclusions. Complete discontinuation of CNI 
replaced by sirolimus introduction was evaluated in the “Heart Spare the Nephron Study” 
intended to include 580 HTx de novo recipeints. (Hunt, 2007 ISHLT). The study was stopped 
after 4 out of 7 sirolimus treated recipients experienced rejection ≥ 3A.  
In paper 3, Group 1 experienced a rapid improvement in renal function. Sixteen HTx 
recipients 5.5 months after HTx, including five patients ongoing in dialysis and 15 long term 
recipeints (8 years post-HTx) were switched overnight from CNI to EVE based 
immunosuppressive therapy. Our results suggest that early CsA withdrawal is safe with 
preserved renal function in long term, also reported in a 5 years follow up of 15 de novo CNI 
free recipients111.  
In our hospital the RENAL study (renal Tx) and the SCHEDULE study (HTx) 
introduced EVE in combination with MMF, steroids and CsA de novo and eliminated CsA 
after 7-11 weeks post-HTx, compared to a traditional CNI medication. In the RENAL study 
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an improvement in mGFR during 12 months follow up was observed despite an increased 
rejection rate and a rather large proportion of drop out patients (in press). The SCHEDULE 
study will complete a 12 months follow up at the end of 2012.  
In paper 3, long term recipients with CsA elimination 8 years after HTx (Group 2) did 
not improve their renal function. With a wide interquartil range, the median creatinine/eGFR 
was unchanged suggesting that established renal fibrosis is irreversible to CsA withdrawal. 
Recipients had histories of diabetes (20 %), general atherosclerosis (53 %) and hypertension 
(73 %), suggesting that also other mechanisms contribute to renal failure43. Although 
improvement was not observed, their renal function stabilized after years of detoriation and 
further renal impairment may have been delayed by the intervention. In contrast to our results, 
renal improvement in long term recipients is reported. This may be explained by earlier 
intervention and a renal function better than our patients before switch28. 
Timing of CNI elimination early after HTx is somewhat controversial.  Guidelines 
have recommended possible CNI elimination 6 and 12 months after HTx22;23, while in renal 
Tx recommendations suggest early conversion between 2 to 6 months. Due to the early CNI 
nephrotoxicity, “there is an obvious advantage for reducing CNI exposure early post-
transplant”8. In general there is no obvious reason to accept different immunosuppression 
strategies for the two organs, besides the penalty of graft loss is greater in HTx than the need 
for recurrent dialysis in renal Tx recipients. As EVE may not have the same 
immunosuppressive power as CNIs112, the cutting edge of EVE therapy is whether we are 
willing to accept an increased risk of milder rejections with the potential benefits of EVE 
therapy: improved renal function, less CMV infection, less development of CAV and less 
development of cancer. Results from the SCHEDULE trial and other ongoing studies will 
hopefully give us some answers that will have future impact on immunosuppressive strategies 
and recommendations. 
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Switch from CsA to EVE can be performed stepwise or as an overnight conversion. 
Overnight switch is easy to perform and interpret and is uncomplicated in long term 
recipients. In a stepwise protocol, interaction between the two drugs requires experience to 
avoid oscillations in blood concentrations and either risk of rejection or renal failure. Shortly 
after HTx a stepwise protocol may be safer in experienced hands and with lower risk of 
rejections with mandatory biopsy surveillance. 
In Group 1, rejections occurred in patients shortly after the switch and with the 
shortest time since HTx. Our rejection incidence is favorable compared to previous reports on 
early CNI freedom31;109. Early CNI freedom resulted in increased rejection rates in the 
RENAL study compared to standard CsA based treatment. Alternative T-cell activation by 
different signal mechanisms may increase rejection risk and suggest that a combination of 
CNI and EVE is required to induce synergistic protection for rejection early postoperatively.  
Timing of CNI elimination and EVE introduction therefore depends on clinical impact and 
prognostic importance of CNI side effect vs. rejection risk of the patients and tolerability of 
higher EVE doses. As the immunosuppressive armentarium is expanding, each patient is now 
able to have an immunosuppressive strategy especially designed for the individual patient at 
risk. 
Representing a potential improvement for patients, successful individualization of a 
growing number of immunosuppressive drugs will demand increased awareness and insight 
from physicians dealing with organ transplantation. 
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9. Conclusion. 
 
 
This thesis has investigated the role of hemodynamics before and after HTx in addition to 
renal failure secondary to nephrotoxic immunosuppression. The following conclusions can be 
drawn: 
 
1. Despite a limited number of patients with irreversible PH, RHC before HTx is important to 
identify patients at risk, but repeated RHC is only needed for patients with severe PH. 
Pulmonary hemodynamics improve early after HTx, but unfavorable post-HTx RHH is 
predictive for survival. 
 
2. ARF occurred in 12 % of HTx recipients, but increased after introduction of iv. CsA. ARF 
was a predictor for short term mortality, but not for the development of chronic renal failure. 
 
3. Early conversion from CNI to EVE based immunosuppression was safe and improved renal 
function in contrast to long term users in whom renal function was unchanged. 
 
4. Low dose EVE and CsA improved renal function in TTx recipients with moderate and 
severe renal failure when EVE was introduced within 5 years after transplantation. 
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